Considerations and challenges with existing treatments for thrombosis in cancer patients

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 5, 2005, Pages

  Schwartz, Rowena N ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Anticoagulants; Dosage; Dosage schedules; Drug interactions; Food; Heparin; Heparins; International Normalized Ratio; Neoplasms; Pharmacokinetics; Plants; Thrombosis; Toxicity; Warfarin

Indexed keywords

AMINOGLUTETHIMIDE; ANTICOAGULANT AGENT; BICALUTAMIDE; CAPECITABINE; ETOPOSIDE; FLUTAMIDE; GEMCITABINE; HEPARIN; IFOSFAMIDE; LOW MOLECULAR WEIGHT HEPARIN; MERCAPTOPURINE; TAMOXIFEN;

ADULT; BLEEDING; BREAST CANCER; CANCER PATIENT; CASE REPORT; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG CROSS REACTIVITY; FEMALE; HUMAN; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MALE; MYELOMA; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; TUMOR THROMBUS;

EID: 28244489876     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Bick RL, Frenkel EP, Walenga J et al. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am. 2005; 19:1-51, v.
2. Raschke RA, Reilly BM, Guidry JR et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993; 119:874-81.
3. Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Prac. 2003; 9:45-85.
4. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000; 18:3078-83.